Indication
Cholestasis
8 clinical trials
10 products
Clinical trial
Multicenter Comparative Randomized Study to Assess Safety and Efficacy and Select the Optimal Dosage Regimen of REMAXA®, Enteric-coated Tablets, in Comparison With REMAXOL®, Solution for Infusions, in Patients With Intrahepatic Cholestasis Caused by Chronic Diffuse Liver DiseasesStatus: Recruiting, Estimated PCD: 2025-05-01
Product
RemaxolProduct
RemaxaProduct
PlaceboClinical trial
Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid MetabolismStatus: Completed, Estimated PCD: 2009-12-01
Product
Cholic AcidsClinical trial
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary CholangitisStatus: Recruiting, Estimated PCD: 2027-02-02
Product
LinerixibatClinical trial
Randomized, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic PruritusStatus: Completed, Estimated PCD: 2021-07-08
Product
EP547Clinical trial
Prospective Evaluation of a Parenteral Omega-3 Fatty Acid Preparation (Omegaven™) in Therapy of Patients With TPN-Induced CholestasisStatus: Completed, Estimated PCD: 2017-10-06
Product
Omegaven™Clinical trial
A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBCStatus: Completed, Estimated PCD: 2022-05-31
Product
HTD1801Clinical trial
Compassionate Use of an Intravenous Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil for Children With Parenteral Nutrition Induced Liver InjuryStatus:
Product
SMOFlipidClinical trial
Jian-She Wang of Children's Hospital of Fudan UniversityStatus: Withdrawn, Estimated PCD: 2023-02-08
Product
4-Phenylbutyrate